Christopher Serjak has more than 25 years experience helping pharmaceutical, biotechnology, and other life sciences clients understand their markets, anticipate future business conditions, and define their “Go Forward” success plan. He is founder of ALIGN2ACTION, Inc., a recognized authority on scenario strategy and competitor gaming.
Christopher has conducted more than 200 strategy engagements across Europe, the US, and Asia. He has extensive experience developing brand, portfolio, and business strategy in therapeutic areas including: immune oncology, inflammatory medicine, respiratory, CNS, anti-infectives, cardiovascular and metabolism, orphan diseases, and many others. Significant recent engagements on the future of reimbursement, health systems, and digital health strategies provide a foundation for understanding the environment in which modern pharmaceutical companies compete.
Prior to ALIGN2ACTION, Christopher was Vice President of Life Sciences Strategy at WoodMackenzie, Inc., where he was responsible for the US consulting practice and for bringing the core competitor gaming and scenario strategy methodologies to the company. Previously, he was a partner at NCRI and a practice leader at NerveWire, Inc., where his clients included a range of Global 1000 companies.